J. Green

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

R. Mosher, W. Sellers, P. Finan, 2010, Proceedings of the National Academy of Sciences.

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Joshua M. Korn, Derek Y. Chiang, Tara L. Naylor, 2015, Nature Medicine.

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Jing Yuan, William R. Sellers, Christoph Lengauer, 2010, Science Translational Medicine.

A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts

Joshua M. Korn, W. Sellers, P. Sorger, 2020, Cancer Research.

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

P. Hammerman, G. Caponigro, F. Mapa, 2020, Clinical Cancer Research.

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts

Joshua M. Korn, W. Sellers, P. Sorger, 2020, bioRxiv.

Discovery of NVP‐LEQ506, a Second‐Generation Inhibitor of Smoothened

John Green, J. Williams, B. Lagu, 2013, ChemMedChem.

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Michael P. Morrissey, W. Sellers, J. Monahan, 2010, Science Translational Medicine.